Literature DB >> 23449515

Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

S H Lim1, W Chang, M Sagong.   

Abstract

PURPOSE: The purpose of this study is to determine the efficacy of half-fluence photodynamic therapy (PDT) depending on the degree of hyperfluorescence based on indocyanine green angiography (ICGA) for treatment of chronic central serous chorioretinopathy (CSC).
METHODS: We conducted a prospective study of 30 eyes of 30 patients with chronic CSC. Half-fluence PDT (25 J/cm(2) for 83 s) with ICGA guidance was applied to the area of choroidal hyperpermeability. The baseline middle-phase ICGA findings were classified as intense or weak hyperfluorescence depending on the degree of hyperpermeability from choriocapillaris. Changes in mean best-corrected visual acuity, resolution of subretinal fluid, recurrence rate, and complications were compared between the two groups.
RESULTS: The baseline ICGA findings showed intense hyperfluorescence in 16 eyes (53.3%) and weak hyperfluorescence in 14 eyes (46.7%). Subretinal fluid showed complete resolution in both the groups 1 month after a single application of half-fluence PDT. Recurrence of subretinal fluid was observed in one of 14 eyes (7.1%) with weak hyperfluorescence and in no eyes (0%) with intense hyperfluorescence. No statistically significant difference in the rate of recurrence was observed between the two groups.
CONCLUSION: Half-fluence PDT appears to be an effective and safe treatment option for patients with chronic CSC regardless of the degree of hyperfluorescence based on ICGA. According to these findings, choroidal hyperpermeability, rather than dysfunction of retinal pigment epithelium, might be more important as primary pathogenesis of chronic CSC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449515      PMCID: PMC3597893          DOI: 10.1038/eye.2013.13

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  29 in total

1.  Histopathological changes following photodynamic therapy in human eyes.

Authors:  Ursula Schmidt-Erfurth; Horst Laqua; Ursula Schlötzer-Schrehard; Arne Viestenz; Gottfried O H Naumann
Journal:  Arch Ophthalmol       Date:  2002-06

2.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

3.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

4.  Experimental serous retinal detachment and focal pigment epithelial damage.

Authors:  A Negi; M F Marmor
Journal:  Arch Ophthalmol       Date:  1984-03

5.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

6.  Retinal pigment epithelium decompensation. I. Clinical features and natural course.

Authors:  A E Jalkh; N Jabbour; M P Avila; C L Trempe; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

7.  Photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Chiara M Eandi; Luca Ventre; Roberta C Rigault de la Longrais; Federico M Grignolo
Journal:  Retina       Date:  2003-12       Impact factor: 4.256

8.  Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Lawrence A Yannuzzi; Jason S Slakter; Nicole E Gross; Richard F Spaide; Danielle L L Costa; Sheau J Huang; James M Klancnik; Alexander Aizman
Journal:  Retina       Date:  2003-06       Impact factor: 4.256

9.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

10.  Cystoid macular degeneration in chronic central serous chorioretinopathy.

Authors:  Tomohiro Iida; Lawrence A Yannuzzi; Richard F Spaide; Natalie Borodoker; Cynthia A Carvalho; Silvana Negrao
Journal:  Retina       Date:  2003-02       Impact factor: 4.256

View more
  10 in total

1.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

2.  Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.

Authors:  Shiri Shulman; Dafna Goldenberg; Roy Schwartz; Zohar Habot-Wilner; Adiel Barak; Nurit Ehrlich; Anat Loewenstein; Michaella Goldstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-21       Impact factor: 3.117

3.  Long term outcomes for patients treated with half-fluence photodynamic therapy for chronic central serous chorioretinopathy: a case series.

Authors:  Jennifer Doyle; Bhaskar Gupta; Irfan Tahir
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

Review 4.  Photodynamic therapy for central serous chorioretinopathy.

Authors:  O C Erikitola; R Crosby-Nwaobi; A J Lotery; S Sivaprasad
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

5.  Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.

Authors:  Yong-Il Shin; Kyeung-Min Kim; Min-Woo Lee; Jung-Yeul Kim; Young-Joon Jo
Journal:  Jpn J Ophthalmol       Date:  2019-12-20       Impact factor: 2.447

6.  The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.

Authors:  Dong Yoon Kim; Soo Geun Joe; Sung Jae Yang; Joo Yong Lee; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2015-05-20

7.  The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case-control study.

Authors:  Abdullah Ozkaya; Ruveyde Garip; Zeynep Alkin; Muhittin Taskapili
Journal:  Int J Retina Vitreous       Date:  2017-06-12

8.  Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy.

Authors:  Erhan Yumusak; Nesrin Buyuktortop Gokcinar; Kemal Ornek
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 9.  Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy

Authors:  Samet Gülkaş; Özlem Şahin
Journal:  Turk J Ophthalmol       Date:  2019-02-28

10.  Automatic analysis of selected choroidal diseases in OCT images of the eye fundus.

Authors:  Robert Koprowski; Slawomir Teper; Zygmunt Wróbel; Edward Wylegala
Journal:  Biomed Eng Online       Date:  2013-11-14       Impact factor: 2.819

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.